Now Available from Camber: Topiramate Extended-Release Capsules, USP
Nearly 40 million Americans experience migraines, according to the American Headache Society, while an additional 3.4 million adults are living with epilepsy in the United States, according to the Epilepsy Foundation.
As millions of Americans manage these neurological conditions, access to affordable treatment options remains essential.
With the launch of topiramate (toe-PYRE-a-mate) extended-release capsules, USP, generic for Trokendi® XR, Camber Pharmaceuticals continues to expand its portfolio of treatment options for these patients.
Camber’s topiramate extended-release capsules, USP are available in 25 mg, 50 mg, 100 mg, and 200 mg strengths in 30-count bottles.
Topiramate extended-release capsules, USP are indicated for the treatment of some epileptic seizures in patients aged 6 years and older, and for the prevention of migraines in patients ages 12 years and older.
For full prescribing information, click here.
Learn more about topiramate extended-release capsules, USP.
Trokendi® XR is a registered trademark of Supernus Pharmaceuticals.
Recent articles
- Now Available from Camber: Topiramate Extended-Release Capsules, USP
- New Product Launch: Clomiphene Citrate Tablets, USP
- Camber Launches Raltegravir Tablets 400 mg
- Specialty Generics: Where Access Meets Affordability
- Buprenorphine and Naloxone Sublingual Films Added to Portfolio
- Buprenorphine and Naloxone Sublingual Tablets Added to Portfolio





